SIRPA and neoplasm: Another emerging strategy to impede CD47/SIRPα interactions is the pharmacological inhibition of glutaminyl cyclases, especially glutaminyl-peptide cyclotransferase like protein (QPCTL), which is highly expressed in tumor cells.